Psychopharmacology of ADHD in pediatrics: current advances and issues

Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral developmental disorder found in 3% to 8% of children and adolescents. An important part of ADHD management is psychopharmacology, which includes stimulants, norepinephrine reuptake inhibitors, alpha-2 agonists, and antidepressants....

Descripción completa

Detalles Bibliográficos
Autores principales: Greydanus, Donald E, Nazeer, Ahsan, Patel, Dilip R
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695228/
https://www.ncbi.nlm.nih.gov/pubmed/19557112
_version_ 1782168173223608320
author Greydanus, Donald E
Nazeer, Ahsan
Patel, Dilip R
author_facet Greydanus, Donald E
Nazeer, Ahsan
Patel, Dilip R
author_sort Greydanus, Donald E
collection PubMed
description Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral developmental disorder found in 3% to 8% of children and adolescents. An important part of ADHD management is psychopharmacology, which includes stimulants, norepinephrine reuptake inhibitors, alpha-2 agonists, and antidepressants. Medications with the best evidence-based support for ADHD management are the stimulants methylphenidate and amphetamine. A number of newer, long-acting stimulants are now available and a number of new medications are considered that are under current research.
format Text
id pubmed-2695228
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26952282009-06-16 Psychopharmacology of ADHD in pediatrics: current advances and issues Greydanus, Donald E Nazeer, Ahsan Patel, Dilip R Neuropsychiatr Dis Treat Review Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral developmental disorder found in 3% to 8% of children and adolescents. An important part of ADHD management is psychopharmacology, which includes stimulants, norepinephrine reuptake inhibitors, alpha-2 agonists, and antidepressants. Medications with the best evidence-based support for ADHD management are the stimulants methylphenidate and amphetamine. A number of newer, long-acting stimulants are now available and a number of new medications are considered that are under current research. Dove Medical Press 2009 2009-04-08 /pmc/articles/PMC2695228/ /pubmed/19557112 Text en © 2009 Greydanus et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Greydanus, Donald E
Nazeer, Ahsan
Patel, Dilip R
Psychopharmacology of ADHD in pediatrics: current advances and issues
title Psychopharmacology of ADHD in pediatrics: current advances and issues
title_full Psychopharmacology of ADHD in pediatrics: current advances and issues
title_fullStr Psychopharmacology of ADHD in pediatrics: current advances and issues
title_full_unstemmed Psychopharmacology of ADHD in pediatrics: current advances and issues
title_short Psychopharmacology of ADHD in pediatrics: current advances and issues
title_sort psychopharmacology of adhd in pediatrics: current advances and issues
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695228/
https://www.ncbi.nlm.nih.gov/pubmed/19557112
work_keys_str_mv AT greydanusdonalde psychopharmacologyofadhdinpediatricscurrentadvancesandissues
AT nazeerahsan psychopharmacologyofadhdinpediatricscurrentadvancesandissues
AT pateldilipr psychopharmacologyofadhdinpediatricscurrentadvancesandissues

Ejemplares similares